¼¼°èÀÇ ÇコÄɾî¿ë ºí·ÏüÀÎ ½ÃÀå
Blockchain in Healthcare
»óǰÄÚµå : 1758043
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 216 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,068,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,204,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÇコÄɾî¿ë ºí·ÏüÀÎ ½ÃÀåÀº 2030³â±îÁö 130¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÇコÄɾî¿ë ºí·ÏüÀÎ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 49.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 130¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÇÁ¶óÀ̺ø ³×Æ®¿öÅ©´Â CAGR 51.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 104¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÆÛºí¸¯ ³×Æ®¿öÅ© ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 40.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 3¾ï 1,220¸¸ ´Þ·¯, Áß±¹Àº CAGR 46.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇコÄɾî¿ë ºí·ÏüÀÎ ½ÃÀåÀº 2024³â¿¡ 3¾ï 1,220¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 19¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 46.2%°¡ µË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 44.9%¿Í 41.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 33.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÇコÄɾî¿ë ºí·ÏüÀÎ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºí·ÏüÀÎÀÌ ÇコÄɾî Çõ½ÅÀÇ ±â¹Ý ±â¼ú·Î ºÎ»óÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ºí·ÏüÀÎ ±â¼úÀº ÇコÄÉ¾î ºÐ¾ßÀÇ º¯ÇõÀÇ ÈûÀ¸·Î ºü¸£°Ô ¹Þ¾Æµé¿©Áö°í ÀÖÀ¸¸ç, µ¥ÀÌÅÍ ÆÄÆíÈ­, º¸¾È Ãë¾à¼º, °ü¸® ÇÁ·Î¼¼½ºÀÇ ºñÈ¿À²¼º µî ÇコÄÉ¾î »ê¾÷¿¡¼­ °¡Àå »Ñ¸® ±íÀº ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ºí·ÏüÀÎÀº ±× Çٽɿ¡¼­ ´Ù¾çÇÑ ÇコÄɾî ÀÌÇØ°ü°èÀÚ°£¿¡ ¾ÈÀüÇϰí Åõ¸íÇÑ µ¥ÀÌÅÍ °øÀ¯¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ºÐ»êÇü ºÒº¯ ¿øÀåÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °íÀ¯ÇÑ ±â´ÉÀº ȯÀÚ ±â·Ï, º¸Çè û±¸, ÀÓ»ó½ÃÇè, °ø±Þ¸Á µ¥ÀÌÅͰ¡ ÀϹÝÀûÀ¸·Î »çÀÏ·ÎÈ­µÇ¾î ÀÖÀ¸¸ç, ´ëÁ¶°¡ ¾î·Á¿î ȯ°æ¿¡¼­ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. º¯Á¶ ¹æÁöµÈ Á¤º¸¿¡ ´ëÇÑ ½Ç½Ã°£ ¾×¼¼½º¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ºí·ÏüÀÎÀº µ¥ÀÌÅÍÀÇ ¹«°á¼ºÀ» ³ôÀ̰í, ±âÁ¸¿¡´Â ¿øÈ°ÇÏ°Ô ÅëÇÕÇÒ ¼ö ¾ø¾ú´ø ½Ã½ºÅÛ °£ÀÇ »óÈ£¿î¿ë¼ºÀ» ÃËÁøÇÕ´Ï´Ù. ÀüÀڰǰ­±â·Ï(EHR)À» ´Ù·ç´Â µ¥ ÀÖÀ¸¸ç, »çÀ̹ö º¸¾È°ú ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ºí·ÏüÀÎÀº ÇöÀç Ç¥ÁØÀ» ¶Ù¾î³Ñ´Â ¿£µåÅõ¿£µå ¾Ïȣȭ¿Í °ËÁõ °¡´ÉÇÑ ¾×¼¼½º Á¦¾î¸¦ Á¦°øÇÕ´Ï´Ù. ¿ø°ÝÀÇ·á, ¿þ¾î·¯ºí, °Ç°­ ¾ÛÀ¸·Î µðÁöÅÐ ÀÇ·á ¼­ºñ½º°¡ ¼ºÀåÇÔ¿¡ µû¶ó ºí·ÏüÀÎÀº ±â±â °£¿¡ »ý¼ºµÇ°í °øÀ¯µÇ´Â ¹Î°¨ÇÑ °Ç°­ µ¥ÀÌÅÍÀÇ ±ÞÁõ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Á¤ºÎ¿Í ±ÔÁ¦±â°üÀº ÀÌ ±â¼úÀÇ ÀáÀç·ÂÀ» Á¡Á¡ ´õ ÀνÄÇϰí ÀÖÀ¸¸ç, ÀÇ·á ±â·Ï °ü¸®, ¾à¹° ÃßÀû¼º, µ¿ÀÇ Ã³¸®¿¡¼­ ºí·ÏüÀÎ ±â¹Ý ¿ëµµ¸¦ Å×½ºÆ®Çϱâ À§ÇÑ ÆÄÀÏ·µ ÇÁ·Î±×·¥ ¹× ¹Î°ü ÆÄÆ®³Ê½ÊÀÌ Àü ¼¼°è¿¡¼­ ¿©·¯ °÷¿¡¼­ ½ÃÀ۵ǰí ÀÖ½À´Ï´Ù. ½Å·Ú¼º°ú Åõ¸í¼ºÀÌ ÇコÄɾî Çõ½ÅÀÇ ÇÙ½É ¿ä¼Ò·Î ¶°¿À¸£¸é¼­, ºí·ÏüÀÎÀº ´Ü¼øÇÑ IT °­È­°¡ ¾Æ´Ñ ÇコÄɾî Á¦°øÀÇ »õ·Î¿î ½Ã´ë¸¦ ¿©´Â ¿øµ¿·ÂÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

´Ù¾çÇÑ ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ºí·ÏüÀÎ ¿ëµµ´Â ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ºí·ÏüÀÎÀÇ Àû¿ë ¹üÀ§°¡ ºü¸£°Ô È®´ëµÇ°í ÀÖÀ¸¸ç, ȯÀÚ µ¥ÀÌÅÍ °ü¸®, ÀǾàǰ °ø±Þ¸Á, ÀÓ»ó½ÃÇè, º¸Çè, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ÀÚ°Ý ÀÎÁõ µî ¿©·¯ ºÐ¾ß¿¡ °ÉÃÄ ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ ±â·Ï ºÐ¾ß¿¡¼­ ºí·ÏüÀÎÀº ȯÀÚ°¡ ¼ÒÀ¯ÇÏ°í °ü¸®ÇÏ¸ç ¿©·¯ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ¾ÈÀüÇÏ°Ô °øÀ¯ÇÒ ¼ö ÀÖ´Â Á¾´ÜÀû °Ç°­ ±â·ÏÀÇ »ý¼ºÀ» ÃËÁøÇÕ´Ï´Ù. ÀÌ´Â ¸¸¼ºÁúȯ °ü¸®¿Í Àü¹® ºÐ¾ß ¹× Áö¿ª °£ Áø·á Á¶Á¤¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. Á¦¾à »ê¾÷¿¡¼­ ºí·ÏüÀÎÀº Á¦Á¶¾÷ü¿¡¼­ ¾à±¹±îÁö ÀǾàǰÀÇ ¿£µå Åõ ¿£µå ÃßÀû¼ºÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á À§Á¶ ÀǾàǰÀ» ¹æÁöÇϱâ À§ÇØ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Åõ¸í¼ºÀº ÁøÇ°¼ºÀ» º¸ÀåÇϰí, ºÎÁ¤ÇàÀ§¸¦ ÁÙÀ̸ç, ÀǾàǰ ȸ¼öÀÇ È¿À²¼ºÀ» ³ôÀÔ´Ï´Ù. ¸¶Âù°¡Áö·Î ºí·ÏüÀÎÀº ÇÁ·ÎÅäÄÝ, ȯÀÚ µ¿ÀÇ, ½ÃÇè °á°ú¿¡ ºÒº¯ÀÇ Å¸ÀÓ½ºÅÆÇÁ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á ÀÓ»ó½ÃÇèÀÇ ¹«°á¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. º¸Çè ¾÷°è¿¡¼­´Â ½º¸¶Æ® ÄÁÆ®·¢Æ®°¡ º¸Çè±Ý û±¸¸¦ °£¼ÒÈ­ÇÏ°í ½ÂÀΰú ÁöºÒÀ» ÀÚµ¿È­ÇÏ´Â µ¿½Ã¿¡ ºÎÁ¤ÇàÀ§¿Í °ü¸® ºñ¿ëÀ» Àý°¨Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÀÇ·á ±â°ü¿¡¼­´Â ºí·ÏüÀÎÀ» Ȱ¿ëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ Àڰݰú ¸éÇ㸦 ½Ç½Ã°£À¸·Î °ËÁõÇϰí, °í¿ëÀ» ½Å¼ÓÇÏ°Ô Ã³¸®Çϰí, Àη À¯µ¿¼ºÀ» °³¼±Çϱâ À§ÇÑ ³ë·ÂÀÌ ½ÃÀ۵ǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ëµµ´Â È¿À²¼ºÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ÇコÄÉ¾î »ýŰè Àü¹Ý¿¡ °ÉÃÄ ½Å·Ú°¡ ±¸ÃàµÇ°í À¯ÁöµÇ´Â ¹æ½ÄÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ´õ ¸¹Àº ÀÇ·á ±â°üÀÌ »óÈ£ ¿î¿ë °¡´ÉÇÑ ºí·ÏüÀÎ Ç÷§ÆûÀ» äÅÃÇÔ¿¡ µû¶ó ÀÌ ±â¼úÀº Æ´»õ ÀÌ¿ë »ç·Ê¿¡¼­ ±â¾÷ Àü¹ÝÀÇ ÅëÇÕÀ¸·Î ÁøÈ­Çϰí ÀÖÀ¸¸ç, º¸´Ù Çù·ÂÀûÀ̰í ȯÀÚ Áß½ÉÀûÀÌ¸ç µ¥ÀÌÅÍ º¸¾ÈÀÌ °­È­µÈ ¹Ì·¡¸¦ ¿¹°íÇϰí ÀÖ½À´Ï´Ù.

±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ¾÷°è Çù·ÂÀº ºí·ÏüÀÎ µµÀÔ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ ºí·ÏüÀÎ µµÀÔÀº ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ºÎ¹® °£ Çù¾÷, »óÈ£¿î¿ë¼º°ú ½Å·Ú¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú Ç¥ÁØÀÇ È®¸³¿¡ Å« ¿µÇâÀ» ¹Þ½À´Ï´Ù. ±ÔÁ¦°¡ ¾ö°ÝÇÑ »ê¾÷ÀÎ ÇコÄɾî´Â ºí·ÏüÀÎÀÇ ±¸ÇöÀÌ ¹Ì±¹ÀÇ HIPAA, À¯·´ÀÇ GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤), ±âŸ Áö¿ªÀÇ µ¥ÀÌÅÍ º¸È£¹ý°ú °°Àº ¾ö°ÝÇÑ ¹ýÀû ¿ä°ÇÀ» ÁؼöÇÏ´ÂÁö È®ÀÎÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦¸¦ ÁؼöÇϱâ À§Çؼ­´Â ÇÁ¶óÀ̹ö½Ã ¹ÙÀÌ µðÀÚÀÎ, ¼±ÅÃÀû µ¥ÀÌÅÍ Á¢±Ù, ÀØÇôÁú ±Ç¸® µîÀÇ ±â´ÉÀ» Áö¿øÇÒ ¼ö ÀÖ´Â ºí·ÏüÀÎ ¾ÆÅ°ÅØÃ³¸¦ ½ÅÁßÇÏ°Ô ¼³°èÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺À» ±Øº¹Çϱâ À§ÇØ ½Ã³Àƽ Çコ ¾ó¶óÀ̾ð½º(Synaptic Health Alliance)³ª ¸Þµð·¹Àú ÇÁ·ÎÁ§Æ®¿Í °°Àº ¾÷°è ÄÁ¼Ò½Ã¾öÀÌ µîÀåÇϰí ÀÖÀ¸¸ç, º¸Çè»ç, °ø±ÞÀÚ, ±â¼ú ±â¾÷, ±ÔÁ¦±â°üÀÌ ¸ð¿© Çõ½ÅÀ» ±Ø´ëÈ­Çϸ鼭 ÄÄÇöóÀ̾𽺠ǥÁØÀ» ÃæÁ·ÇÏ´Â ºí·ÏüÀÎ ÇÁ·¹ÀÓ¿öÅ©¸¦ ÄÄÇöóÀ̾𽺠±âÁØÀ» ÃæÁ·ÇÏ´Â ºí·ÏüÀÎ ÇÁ·¹ÀÓ¿öÅ©¸¦ °øµ¿ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¥ÀÌÅÍ ±³È¯ ¹× ½Ã½ºÅÛ »óÈ£¿î¿ë¼ºÀ» À§ÇÑ °øÅë ÇÁ·ÎÅäÄÝÀ» ¸¸µå´Â µ¥¿¡µµ Çù¾÷ÀÌ ÇʼöÀûÀ̸ç, ÀÌ´Â ´ë±Ô¸ð È®»êÀÇ Áß¿äÇÑ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Resources)¿Í °°Àº ±âÁ¸ ÇコÄÉ¾î »óÈ£¿î¿ë¼º ÇÁ·¹ÀÓ¿öÅ©¿¡ ºí·ÏüÀÎÀ» ÅëÇÕÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø°ú »÷µå¹Ú½º Á¦µµ´Â ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ ºí·ÏüÀÎ ½ÇÇèÀ» ´õ¿í °¡¼ÓÈ­ÇÏ¿© À§ÇèÀ» ÁÙÀ̰í ROI¸¦ °ËÁõÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌÇØ°ü°èÀÚµéÀÌ °æÀïÀÇ º®À» ³Ñ¾î Çù·ÂÇÒ ¼ö ÀÖ´ÂÁö¿¡ µû¶ó ºí·ÏüÀÎÀÌ ¾ó¸¶³ª »¡¸® ÆÄÀÏ·µ¿¡¼­ ´ëÁßÈ­ ´Ü°è·Î ³Ñ¾î°¥ ¼ö ÀÖÀ»Áö°¡ °áÁ¤µÉ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ »óȲ¿¡¼­ ±ÔÁ¦ ¸íȮȭ, ÀÌÇØ°ü°èÀÚ Çù·Â, È®Àå °¡´ÉÇÑ ±â¼ú Ç¥ÁØÀº ÇコÄÉ¾î ¾÷¹«ÀÇ ÁÖ·ù¿¡ ºí·ÏüÀÎÀ» ÅëÇÕÇÏ´Â ¼Óµµ¿Í ¹üÀ§¸¦ Çü¼ºÇÏ´Â Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ºí·ÏüÀÎ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÇコÄÉ¾î ºÐ¾ßÀÇ ºí·ÏüÀÎ ½ÃÀå ¼ºÀåÀº ±â¼ú ¹ßÀü, ¾÷°è ¿ì¼±¼øÀ§ÀÇ º¯È­, µ¥ÀÌÅÍ Åõ¸í¼º°ú º¸¾È¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¿ì¼±, EHR°ú ¿ø°Ý ¸ð´ÏÅ͸µ ±â±â¿¡¼­ À¯Àüü µ¥ÀÌÅͺ£À̽º¿¡ À̸£±â±îÁö µðÁöÅÐ °Ç°­ µ¥ÀÌÅͰ¡ Æø¹ßÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó À̸¦ ÀúÀå, °øÀ¯, ¾×¼¼½º °ü¸®Çϱâ À§ÇÑ °ß°íÇÏ°í º¯Á¶ ¹æÁöµÈ ½Ã½ºÅÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. µÑ°, µ¥ÀÌÅÍ À¯Ãâ°ú ÀÇ·á »ç±â Áõ°¡·Î ÀÎÇØ ÀÇ·á±â°üÀº ±âÁ¸ IT ÀÎÇÁ¶ó¿¡ ´ëÇÑ º¸´Ù ¾ÈÀüÇÑ ´ë¾ÈÀ» ã°í ÀÖÀ¸¸ç, ºí·ÏüÀÎÀº ½Ç½Ã°£ ÃßÀû°ú °¨»ç °¡´É¼º°ú ½Å·Ú¼ºÀ» ³ôÀÌ´Â ¾Ïȣȭ ¾ÈÀüÀåºñ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¿©·¯ ÀÇ·á±â°üÀÇ Áø·á Á¶Á¤, ¿ø°ÝÀÇ·áÀÇ È®´ë, ¼¼°è °ø±Þ¸ÁÀ¸·Î ´ëÇ¥µÇ´Â ÇコÄɾî Á¦°øÀÇ º¹À⼺À¸·Î ÀÎÇØ ºí·ÏüÀÎÀÌ °¡´ÉÇÏ°Ô ÇÏ´Â µ¥ÀÌÅÍ °ü¸®¿¡ ´ëÇÑ ºÐ»êÇü Á¢±Ù ¹æ½ÄÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Á¦¾à»çµéÀº ƯÈ÷ ¼¼°è °ø±Þ¸ÁÀÇ È¥¶õÀ¸·Î ÀÎÇØ ÀǾàǰ Á¦Á¶ ¹× À¯ÅëÀÇ Åõ¸í¼º°ú ÃßÀû¼ºÀ» È®º¸Çϱâ À§ÇØ ºí·ÏüÀÎÀÇ Ã¤ÅÃÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¡Ä¡ ±â¹Ý ÀÇ·á ¹× È¯ÀÚ Á᫐ ¸ðµ¨·ÎÀÇ Àüȯµµ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, Åõ¸íÇÑ µ¥ÀÌÅÍ È帧°ú °ËÁõ °¡´ÉÇÑ È¯ÀÚ °á°ú¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ºí·ÏüÀÎ ÇコÄÉ¾î ½ºÅ¸Æ®¾÷¿¡ ´ëÇÑ º¥Ã³Ä³ÇÇÅÐÀÇ ÅõÀÚ¿Í ±â¾÷ÀÇ ¿¬±¸°³¹ßµµ ƯÈ÷ ¹Ì±¹, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç µî ½ÃÀå¿¡¼­ Çõ½Å°ú È®ÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ȯÀÚµéÀÇ ±â´ëÄ¡°¡ ÁøÈ­Çϰí ÀÖÀ¸¸ç, ´õ ¸¹Àº °³ÀεéÀÌ ÀÚ½ÅÀÇ °Ç°­ Á¤º¸¿Í ±× »ç¿ë ¹æ½Ä¿¡ ´ëÇÑ ÅëÁ¦±ÇÀ» ¿ä±¸ÇÔ¿¡ µû¶ó ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ÁöºÒÀڴ ȯÀÚ ÁÖµµ±ÇÀ» °­È­ÇÏ´Â ¼Ö·ç¼ÇÀ» µµÀÔÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ºí·ÏüÀÎ ±â¼úÀÌ ÇコÄɾ »Ñ¸®¸¦ ³»¸®°í º¸´Ù ¾ÈÀüÇϰí È¿À²ÀûÀÌ¸ç ½Å·Ú¿¡ ±â¹ÝÇÑ ½Ã½ºÅÛÀ¸·Î º¯¸ðÇÒ ¼ö ÀÖ´Â ºñ¿ÁÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

³×Æ®¿öÅ©(ºñ°ø°³ ³×Æ®¿öÅ©, °ø°³ ³×Æ®¿öÅ©), ÃÖÁ¾ ¿ëµµ(¹ÙÀÌ¿ÀÀǾàǰ¡¤ÀÇ·á±â±â ȸ»ç, ÇÁ·Î¹ÙÀÌ´õ, ÁöºÒÀÚ), ¾ÖÇø®ÄÉÀ̼Ç(°ø±Þ¸Á °ü¸® ¾ÖÇø®ÄÉÀ̼Ç, ÀÓ»ó½ÃÇè ¾ÖÇø®ÄÉÀ̼Ç, ÀÓ»ó µ¥ÀÌÅÍ ±³È¯ ¾ÖÇø®ÄÉÀ̼Ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 36»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Blockchain in Healthcare Market to Reach US$13.0 Billion by 2030

The global market for Blockchain in Healthcare estimated at US$1.2 Billion in the year 2024, is expected to reach US$13.0 Billion by 2030, growing at a CAGR of 49.0% over the analysis period 2024-2030. Private Network, one of the segments analyzed in the report, is expected to record a 51.8% CAGR and reach US$10.4 Billion by the end of the analysis period. Growth in the Public Network segment is estimated at 40.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$312.2 Million While China is Forecast to Grow at 46.2% CAGR

The Blockchain in Healthcare market in the U.S. is estimated at US$312.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 46.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 44.9% and 41.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 33.2% CAGR.

Global Blockchain in Healthcare Market - Key Trends & Drivers Summarized

Why Is Blockchain Emerging as a Foundational Technology in Healthcare Innovation?

Blockchain technology is rapidly being embraced as a transformative force in healthcare, promising to address some of the most persistent challenges in the industry such as data fragmentation, security vulnerabilities, and inefficiencies in administrative processes. At its core, blockchain provides a decentralized, immutable ledger that enables secure and transparent data sharing across diverse healthcare stakeholders. This unique capability is particularly important in an environment where patient records, insurance claims, clinical trials, and supply chain data are typically siloed and difficult to reconcile. By enabling real-time access to tamper-proof information, blockchain enhances data integrity and facilitates interoperability between systems that traditionally have lacked seamless integration. The heightened need for cybersecurity and privacy in handling electronic health records (EHRs) is another major driver, with blockchain offering end-to-end encryption and verifiable access control that exceed current standards. As digital health services grow-driven by telemedicine, wearables, and health apps-blockchain presents a solution for managing the surge in sensitive health data being generated and shared across devices. Moreover, governments and regulatory bodies are increasingly recognizing the technology’s potential, with several pilot programs and public-private partnerships being launched globally to test blockchain-based applications in health record management, drug traceability, and consent handling. As trust and transparency become critical pillars in healthcare transformation, blockchain is positioning itself not merely as an IT enhancement but as a foundational enabler of a new era in healthcare delivery.

How Are Blockchain Applications Evolving Across Different Healthcare Segments?

The scope of blockchain in healthcare is expanding rapidly, with applications emerging across multiple segments including patient data management, pharmaceutical supply chains, clinical trials, insurance, and provider credentialing. In the realm of patient records, blockchain facilitates the creation of longitudinal health records that patients can own, control, and share securely with multiple providers. This is particularly valuable in managing chronic diseases and coordinating care across specialties and geographic regions. In the pharmaceutical industry, blockchain is being deployed to combat counterfeit drugs by enabling end-to-end traceability of medications from manufacturer to pharmacy. Such transparency ensures authenticity, reduces fraud, and enhances drug recall efficiency. Similarly, blockchain is improving the integrity of clinical trials by providing immutable timestamped data for protocols, patient consent, and trial results-ensuring regulatory compliance and minimizing the risk of data manipulation. In insurance, smart contracts are streamlining claims adjudication, automating approvals and payments while reducing fraud and administrative costs. Meanwhile, healthcare organizations are beginning to use blockchain to validate provider credentials and licensure in real-time, speeding up hiring and improving workforce mobility. These applications are not only improving efficiency but are also reshaping how trust is built and maintained across the healthcare ecosystem. As more healthcare entities adopt interoperable blockchain platforms, the technology is evolving from niche use cases to enterprise-wide integration, heralding a more collaborative, patient-centric, and data-secure future.

How Do Regulatory Frameworks and Industry Collaboration Influence Blockchain Adoption?

The adoption of blockchain in healthcare is deeply influenced by regulatory frameworks, cross-sector collaboration, and the establishment of technical standards that enable interoperability and trust. As a highly regulated industry, healthcare must ensure that blockchain implementations comply with strict legal requirements such as HIPAA in the U.S., GDPR in Europe, and other regional data protection laws. These regulations necessitate careful design of blockchain architectures that can support privacy by design, selective data access, and right-to-be-forgotten functionalities-capabilities that challenge the traditionally immutable nature of blockchain. To navigate these complexities, industry consortia such as the Synaptic Health Alliance and the MediLedger Project are emerging, bringing together insurers, providers, technology firms, and regulatory bodies to co-develop blockchain frameworks that meet compliance standards while maximizing innovation. Collaboration is also essential in creating common protocols for data exchange and system interoperability, which remain key barriers to large-scale deployment. Standards development organizations like HL7 and IEEE are working on incorporating blockchain into existing healthcare interoperability frameworks such as FHIR (Fast Healthcare Interoperability Resources). Government funding and sandbox initiatives are further accelerating blockchain experimentation in healthcare, helping mitigate risk and validate ROI. The ability of stakeholders to work collectively-across competitive boundaries-will largely determine how quickly blockchain can move from pilots to widespread adoption. In this context, regulatory clarity, stakeholder alignment, and scalable technical standards are becoming critical enablers that will shape the pace and scope of blockchain integration into mainstream healthcare operations.

What Key Factors Are Driving Growth in the Blockchain in Healthcare Market?

The growth in the blockchain in healthcare market is driven by several factors rooted in technology advancements, shifting industry priorities, and growing demand for data transparency and security. First and foremost, the explosion of digital health data-from EHRs and remote monitoring devices to genomic databases-requires robust, tamper-proof systems for storage, sharing, and access management, a need that blockchain is uniquely positioned to fulfill. Second, the rising incidence of data breaches and healthcare fraud is pushing institutions to seek more secure alternatives to traditional IT infrastructure, with blockchain offering real-time tracking and cryptographic safeguards that enhance auditability and trust. Additionally, the growing complexity of healthcare delivery-marked by multi-provider care coordination, telemedicine expansion, and global supply chains-demands a decentralized approach to data management that blockchain enables. Pharmaceutical companies, for example, are increasingly adopting blockchain to ensure transparency and traceability in drug manufacturing and distribution, especially in the wake of global supply chain disruptions. Another significant driver is the shift toward value-based care and patient-centric models, which require transparent data flows and verifiable patient outcomes-functions that blockchain can support through smart contracts and immutable patient records. Venture capital investment and corporate R&D in blockchain healthcare startups are also accelerating innovation and deployment, particularly in markets such as the U.S., Europe, and Asia-Pacific. Finally, patient expectations are evolving, with more individuals demanding control over their health information and how it is used, prompting providers and payers to adopt solutions that empower patient agency. Together, these factors are creating a fertile environment for blockchain technologies to take root in healthcare, transforming it into a more secure, efficient, and trust-based system.

SCOPE OF STUDY:

The report analyzes the Blockchain in Healthcare market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Network (Private Network, Public Network); End-Use (Biopharma & Medical Device Companies End-Use, Providers End-Use, Payers End-Use); Application (Supply Chain Management Application, Clinical Trials Application, Clinical Data Exchange Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â